08 jun: Damark/vismand: Regeringen skal finde nye penge
10 jun: Overskud i APM´s containerforretning
08-06-2012 23:55:00

J&J to Record $600 Million Charge in 2Q

Relateret indhold
Relateret debat
13 maj - 
We offer fresh cut bank instrument for lease/sale, such..

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:55 ET (21:55 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Vind: Nyt australsk storprojekt undervejs

02-07-2015 16:08:15
Den australske vindmøllesektor ser ud til at være på vej op i omdrejninger igen, efter at landets politikere for nylig blev enige om at forbedre vilkårene for v..

Vestas-konkurrent løfter omsætning og indtjening

02-07-2015 13:12:59
Den tyske vindmølleproducent Senvion kan glæde sig over fremgang på både top- og bundlinje i sit forskudte regnskabsår 2014/15, der sluttede ved udgangen af mar..

Novo tror fortsat på Tresiba-fremtid i Tyskland

02-07-2015 10:12:40
Novo Nordisk stoppede onsdag sin distribution af Tresiba i Tyskland, efter at Tysklands nationale sammenslutning af sygekasser og medicinalkoncernen ikke kunne ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Grækenland: Finansminister siger op ved "ja"-stemme - medie
2
Vestas-konkurrent indgår aftale om 1 GW
3
Gældsplagede grækere får endnu flere kredithug
4
Svensk aktie brændt af efter fusionsbøvl
5
Aktier/tendens: Let optimisme trods græsk stilstand

Relaterede aktiekurser

Johnson & Johnson 98,44 0,0% Fald i aktiekurs
Omnicare Inc 94,29 0,1% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
2. juli 2015 23:29:17
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150702.1 - EUROWEB4 - 2015-07-02 23:29:17 - 2015-07-02 23:29:17 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x